

# Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

## WS Bellevue Healthcare Fund

GBP Accumulation Class (GB00BN0ZBH90)  
a Sub-Fund of WS Bellevue Funds (UK) OEIC

Waystone Management (UK) Limited is the Authorised Corporate Director of the Fund

## OBJECTIVES AND INVESTMENT POLICY

### Investment Objective

The Fund aims to achieve capital growth of at least 10% p.a., net of fees, over a rolling three-year period.

Capital is at risk and there is no guarantee that the positive return will be achieved over that specific, or any, time period.

### Investment Policy

At least 90% of the Fund is invested in listed shares of healthcare companies based anywhere in the world. There are no restrictions on the constituents of the Fund's portfolio by index benchmark, geography, market capitalisation or healthcare industry sub-sector. At times, the Fund may generally be invested in shares listed in the United States. The Fund is concentrated as it has a maximum of 40 holdings.

The Fund invests in the global healthcare industry including pharmaceuticals, biotechnology, medical devices and equipment, healthcare insurers, facility operators, information technology (where the product or service supports, supplies or services the delivery of healthcare), drug retail, consumer healthcare, distribution services and research tools.

The Fund may also invest in American depository receipts or convertible instruments issued by healthcare companies, invest in future equity issues by such companies, money market instruments and cash.

The Fund does not intend to invest in collective investment schemes but in the event that it does, such investment is limited to no more than 10% of the Fund.

The Fund may only use derivatives for Efficient Portfolio Management. The use of derivatives for this purpose is not likely to affect the risk profile of the Fund.

For full investment objectives and policy information please refer to the prospectus.

### Benchmark

The Fund is actively managed without reference to a benchmark and the Investment Manager has full discretion over the composition of the Fund's portfolio, subject to the stated investment objective and investment policy.

The comparative benchmark for the Fund is the MSCI World Healthcare Index (in sterling). Whilst the Benchmark is used to measure the performance of the Fund, the Fund does not seek to replicate the Benchmark in constructing its portfolio. The portfolio may, therefore, diverge substantially from the constituents of the Benchmark.

### Income

Any income the Fund generates in respect of your investment is rolled up (accumulated) and included in the value of your shares.


### Fund Currency

The base currency of the Fund is GBP.

### Subscription and Redemption

You can buy or sell shares in the Fund on each UK business day.

## RISK AND REWARD PROFILE



### Risk Disclaimer

The Risk and Reward Indicator table demonstrates where the Fund ranks in terms of its potential risk and reward. The higher the rank the greater the potential reward but the greater the risk of losing money. The shaded area in the table above shows the Fund's ranking on the Risk and Reward Indicator.

Please note that even the lowest risk class can lose you money and that extreme market circumstances can mean you suffer severe losses in all cases.

Please note the Fund's risk category may change in the future.

### Why is the fund in the specific category?

This Fund is ranked 7. This is due to historical price movement of such investments.

### The indicator does not take into account the following risks of investing in this Fund:

**Market risk:** The investments of the Fund are subject to normal market fluctuations and other risks inherent in investing in securities.

**Diversification Risk:** Some Funds may have a portfolio of assets which is concentrated in individual countries, companies or market sectors. If one of these factors underperformed, it would have a greater effect than would be the case in a more diversified portfolio where the risk is more widely spread.

**Interest Rate Risk:** Fixed interest securities are affected by trends in interest rates and inflation. If interest rates go up the value of capital may fall and vice versa. Inflation will also decrease the real value of capital. The value of a fixed interest security is also affected by its credit rating.

**Currency exchange rates:** Currency fluctuations may adversely affect the value of a Fund's investments and, depending on an investor's currency of reference, currency fluctuations may adversely affect the value of his investment in Shares.

**Counterparty risk:** The Fund will be subject to the risk of the inability of any counterparty to perform with respect to transactions, whether due to insolvency, bankruptcy or other causes.

Further details on risk factors that apply to this Fund are set out in the Risk Factors section of the prospectus.

## CHARGES

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

### One-off charges taken before or after the investment

**Entry charge** 0.00%

**Exit charge** 0.00%

### Charges debited to the Fund over a year

**Ongoing charge** 1.23%

### Charges debited to the Fund under certain specific conditions

**Performance fee:** Not applicable

The entry and exit charges are maximum figures. In certain cases you may pay less - you can find this out from your financial advisor.

The ongoing charges figure is estimated as at 24/11/2022 due to the annual management charge reverting to 0.99% pa from the Investment Manager's previously subsidised charge of 0.04% pa.

It excludes the costs of buying or selling assets for the Fund (unless these assets are shares of another fund).

You may also be charged a dilution levy on entry to or exit the Fund.

For more information about charges, please see Valuation, Charges and Income section of the prospectus, which is available at [www.waystone.com](http://www.waystone.com).

## PAST PERFORMANCE

Fund launch date: 31 August 2021.

Share/unit class launch date: 31 August 2021

Past performance is calculated in GBP.

Past performance is not a reliable indication of future performance.

Past performance takes into account all charges and costs.

## PRACTICAL INFORMATION

### Depository

The Depository of the Fund is CACEIS Bank, UK Branch.

### Further Information

You can obtain further detailed information regarding the Fund and the OEIC, its prospectus, its latest annual reports and any subsequent half yearly reports free of charge from the Authorised Corporate Director by calling **0203 997 2460** or visiting [www.waystone.com](http://www.waystone.com) and also by request in writing to Waystone Management (UK) Limited, 2nd Floor, 20-22 Bedford Row, London, WC1R 4EB.

### Remuneration Policy

Details of Waystone's remuneration policy (including a description of how remuneration and benefits are calculated and the composition of the remuneration committee) are available at [www.waystone.com](http://www.waystone.com) or by requesting a paper copy free of charge (see above for contact details).

### Conversion of units/shares

This document describes only one share class, GBP Accumulation Class of the Fund. You can exchange your shares for shares of other funds of the company as and when available. Information as to how to exercise the right is in the "Switching" section of the prospectus.

### Price Publication

You can check the latest prices by calling **0330 0240 785** or visiting our website [www.waystone.com](http://www.waystone.com).

### Tax Legislation

The Fund is subject to the tax laws of the United Kingdom. Depending on your own country of residence, this might have an impact on your investment.

### Liability Statement

Waystone Management (UK) Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.